Highly sensitive spectrofluorimetric determination of trace amounts of prulifloxacin using the aluminium(III)-prulifloxacin system

Luminescence

Volumn 23, Issue 6, 2008, Pages 429-433

  Yu, Fengshan ^a   Liu, Weizhou ^a   Chen, Fang ^a   Cai, Ping ^b  

^a HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^b WUHAN UNIVERSITY   (China)

Author keywords

Al(III); Prulifloxacin; Spectrofluorimetry

Indexed keywords

ALUMINUM COMPOUNDS;

AL(III); ENHANCED FLUORESCENCE; FLUORESCENCE INTENSITIES; LINEAR RELATIONSHIPS; PRULIFLOXACIN; SODIUM DODECYL BENZENE SULPHONATE; SPECTROFLUORIMETRIC DETERMINATION; SPECTROFLUORIMETRIC METHODS; SPECTROFLUORIMETRY; TRACE AMOUNTS;

FLUORESCENCE;

EID: 56849114560     PISSN: 15227235     EISSN: 15227243     Source Type: Journal    
DOI: 10.1002/bio.1075     Document Type: Article

References (12)

1. Keam SJ, Perry CM. Prulifloxacin. Drugs 2004; 64: 2221-2234.
2. Okuhama Y, Momota K, Morino A. Pharmacokinetics of prulifloxacin. 1st communication: absorption, distribution and excretion in rats, dogs and monkeys after a single administration. Arzneim-Forsch. 1997; 47: 276-284.
3. Nakashima M, Uematsu T, Kosuge K, Okuhama Y, Morino A, Ozaki M, Takebe Y. Pharmacokinetics and safety of NM441, a new quinolone, in healthy male volunteers. J. Clin. Pharmacol. 1994; 34: 930-937.
4. Tougou K, Nakamura A, Watanabe S, Okuyama Y, Morino A. Paraoxonase has a major role in the hydrolysis of prulifloxacin (NM441), a prodrug of a new antibacterial agent. Drugs Metab. Dispos. 1998; 26: 355-359.
5. Picollo R, Brion N, Gualano V, Millerioux L, Marchetti M, Rosignoli MT, Dionisio P. Pharmacokinetics and tolerability of prulifloxacin after single oral administration. Arzneim-Forsch. 2003; 53: 201-205.
6. Wen J, Zhu ZY, Hong ZY, Fei Y, Lin M, Fan GR, Wu YT. Determination of the active metabolite of prulifloxacin in human plasma by HPLC with fluorescence detection. Chromatography 2007; 66: 37-41.
7. Guo LX, Qi ML, Jin X, Wang P, Zhao HQ. Determination of the active metabolite of prulifloxacin in human plasma by liquid chromatography-tandem mass spectrometry. J. Chromatogr. B 2006; 832: 280-285.
8. Du LM, Cao XM, Wu HY. Direct determination of enoxacin in human plasma by micellar enhancing effect-synchronous fluorimetry. Chin. J. Anal. Chem. 2003; 31: 1330-1332.
9. Han YX, Wu X, Yang JH, Sun SN. The fluorescence characteristic of the yttrium-norfloxacin system and its analytical application. J. Pharm. Biomed. Anal. 2005; 38: 528-531.
10. Ocana JA, Callejon M, Barragan FJ. Determination of trovafloxacin in human serum by time resolved terbium-sensitized luminescence. Eur. J. Pharmaceut. Sci. 2001; 13: 297-301.
11. Tong CL, Zhu Y, Liu WP. Study on the co-luminescence system of Dy-Gd-1,6-bis(1′-phenyl-3′-methyl-5′-pyrazol-4′-one) hexanedione-cetyltrimethyl lammonium bromide and its analytical application. Analyst 2001; 126: 1168-1171.
12. Shah SS, Naeem K, Shah SWH, Laghari GM. Differential absorbance measurements of amphiphilic hemicyanine dyes, solubilization study in anionic surfactant. Colloids Surfact. A 2000; 168: 77-85.